Pulmonary toxicity of antineoplastic agents.
Pulmonary parenchymal or pleural reactions to chemotherapeutic agents used in the management of patients with malignant diseases are being recognized with increasing frequency. Alkylating agents, asparaginase, bleomycin, methotrexate and procarbazine have all been implicated. Some of the reactions, such as the rare procarbazine pleuritis and pneumonitis, represent hypersensitivity phenomena. Others, such as alkylating agent pulmonary toxicity, appear to be direct toxic effects of the drugs. The severity of the toxicity is variable. The appearance of these pulmonary changes must be differentiated from tumor progression or a variety of possible infections. The awareness of possible pulmonary toxicity is of great importance since early discontinuation of the agent following the first hint of pulmonary toxicity may allow partial or complete reversal of the process. Continued therapy in the face of drug-related pulmonary toxicity may enhance the likelihood of irreversible pulmonary compromise with respiratory failure and death.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects
D000970:Antineoplastic Agents; D001761:Bleomycin; D008727:Methotrexate